top of page

Harbinger Health’s Steve Hahn on the science of early cancer Dx after raising a $140M Series B

Steve Hahn describes how Harbinger Health is trying to catch the earliest signals of cancer, and how physicians and patients might use this information.



Commentaires


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page